Among older patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL), treatment with fixed-duration Epkinly (epcoritamab-bysp) plus dose-attenuated Rituxan (rituximab) plus cyclophosphamide ...
Epcoritamab combined with R-mini-CHOP showed a 93% overall response rate in elderly DLBCL patients, with 86% achieving complete response. At two years, 79% of patients remained in response, and 90% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback